骨保护蛋白/护骨素抗体
规格：1mg/1ml
英文名： OPG
别名： MGC29565; OCIF; OPG; Osteoclastogenesis Inhibitory Factor; TNFRSF 11B; TNFRSF11B; TR 1; TR1; Tumor Necrosis Factor Receptor Superfamily Member 11b; TR11B_HUMAN.
分子量： 43kDa
储存液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce
克隆类型：Polyclonal
亚型：IgG
纯化方法：affinity purified by Protein A
**原：KLH conjugated synthetic peptide derived from human OPG
交叉反应：Human, Mouse, Rat, Dog, Cow,
骨保护蛋白/护骨素抗体细胞定位：分泌型蛋白
产品介绍：background: Osteoprotegerin (OPG, or osteoclastogenesis inhibitory factor) is a secretory glycoprotein belonging to TNF receptor superfamily. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. OPG acts as a soluble factor in the regulation of bone mass and may be beneficial in the treatment of osteoporosis with increased osteoclast activity. OPG consists of 401 amino acids with a molecular weight of 44 kDa as a monomer and 90 kDa as a disulphide-linked dimer. Function: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone 骨保护蛋白/护骨素抗体homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Subunit: Homodimer. Subcellular Location: Secreted. Tissue Specificity: Highly expressed in ***** lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung. Post-translational modifications: N-glycosylated. Contains sialic acid residues. The N-terminus is blocked. DISEASE: Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate骨保护蛋白/护骨素抗体 of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal. Similarity: Contains 2 death domains. Contains 4 TNFR-Cys repeats. Gene ID: 4982 Database links: Entrez Gene: 4982 Human Omim: 602643 Human SwissProt: O00300 Human Unigene: 81791 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 护骨素又称护骨因子(osteorotegenin,OPG)、骨保护蛋白、破骨细胞生成抑制因子、骨保护素、破骨细胞抑制生成因子（osteoclastogenesis inhibitory factor，OCIF） OPG属于TNF受体超家族，主要功能是抑制破骨细胞的分化、成熟破骨细胞的骨吸收活性，并诱导其凋亡。
骨保护蛋白/护骨素抗体产品应用：WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
研究领域：肿瘤 细胞生物 **学 信号转导 骨髓细胞
储存条件： Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
来源： Rabbit
外观： Lyophilized or Liquid
- 温馨提示：为规避购买风险，建议您在购买前务必确认供应商资质与产品质量。
- 免责申明：以上内容为注册会员自行发布，若信息的真实性、合法性存在争议，平台将会监督协助处理，欢迎举报